Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05653180 | IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01898104 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer(V-shoRT-R3) | unknown | Phase 1 / Phase 2 | 152 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05777707 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | unknown | Phase 1 / Phase 2 | 89 | Beijing Friendship HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05675462 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 25 | Fudan UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05536427 | Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 24 | Peking Union Medical College HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05738447 | Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma | unknown | Phase 1 | 9 | West China HospitalOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05167448 | A Study of ES104 in Patients With Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 58 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05721872 | Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 38 | Nazarbayev UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT04417764 | TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | unknown | Phase 1 | 10 | Central South UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05225116 | Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04911959 | Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | unknown | Phase 1 / Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04612504 | SynOV1.1 Intratumoral Injection Study | unknown | Phase 1 | 15 | Beijing Syngentech Co., Ltd.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT03995017 | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma(RiME) | unknown | Phase 1 / Phase 2 | 34 | University of Kansas Medical CenterOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04612530 | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | unknown | Phase 1 | 18 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05643417 | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy | unknown | Phase 1 | 80 | Fudan UniversityOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05622825 | Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers | unknown | Phase 1 / Phase 2 | 15 | National Taiwan University HospitalOTHER | 0 | Nov 21, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05608785 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | unknown | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603039 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 80 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05016869 | Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 48 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05024812 | Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 1 / Phase 2 | 64 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05059821 | Personalized Cancer Vaccine in Egyptian Cancer Patients(PROVE) | unknown | Phase 1 | 10 | zeinab ahmed yousif hasan ashourOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05439993 | Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma | unknown | Phase 1 / Phase 2 | 42 | Hallym University Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04258072 | Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | unknown | Phase 1 | 24 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03626922 | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | unknown | Phase 1 | 33 | NSABP Foundation IncNETWORK | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05396326 | A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 0 | May 31, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05339321 | Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC | unknown | Phase 1 | 36 | Peking Union Medical College HospitalOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05363722 | A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 80 | Shanghai Zhongshan HospitalOTHER | 0 | May 6, 2022 | clinicaltrials |
| NCT04460066 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT04564313 | Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation | unknown | Phase 1 | 20 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Apr 3, 2023source: clinicaltrials